Navigation Links
WaferGen Announces that University of Texas Southwestern Medical Center Demonstrates Utility of New SmartChip(TM) Nano-Dispenser with WaferGen's SmartChip(TM) High-throughput Real-Time PCR System
Date:11/12/2009

FREMONT, Calif., Nov. 12 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art genetic analysis systems, today announced that the University of Texas Southwestern Medical Center demonstrated the utility of WaferGen's new proprietary SmartChip(TM) Nano-dispenser. The Nano-dispenser is used for loading samples and enzymes onto content-ready SmartChips for use with WaferGen's SmartChip(TM) Real-Time PCR System. The SmartChip Real-Time PCR System is designed to boost pathway-based gene discovery and exploration enabling researchers to discover new gene markers that could be missed using current microarray methods of discovery.

"The SmartChip Nano-dispenser enables the loading of a single sample into 5,184 nano-wells in a single step in approximately 20 minutes--at least three times faster than standard nano-dispensers," said Spencer Brown, Ph.D., Director of Plastic Surgery Research, Nancy Lee and Perry Bass of the Advanced Wound Healing Laboratory at UT Southwestern. "It is simple, easy to use, reliable, and cost-effective since we don't need to purchase elaborate and expensive equipment. Furthermore, its small footprint provides an added advantage of requiring less space. This contributes to our ability to use the SmartChip system to conduct gene expression research at a fraction of the time and cost of existing instrument systems."

"By demonstrating the utility of the SmartChip Nano-dispenser, UT Southwestern has provided additional verification of the role that the SmartChip system can play in decreasing research time and increasing the cost-efficiency of validating relevant gene expression biomarkers, and eventually assessing their impact on patient response to treatment," said Alnoor Shivji, Chairman and CEO, WaferGen. "This decrease in research time has broad economic implications for researchers discovering biomarkers and across the drug development industry, particularly for companies seeking ways to reduce time to market for their therapeutics or diagnostic products."

In January 2009, WaferGen and UT Southwestern established a collaboration under which UT Southwestern is conducting novel research projects using the SmartChip Real-Time PCR System in order to identify and validate gene expression biomarkers related to wound healing. Subsequent to this agreement, in March 2009, WaferGen and UT Southwestern established a novel wound healing research collaboration with IR BioSciences Holdings, Inc., a development-stage biotechnology company focused on the research, development and licensing of ImmuneRegen's wound healing drug candidate, Homspera®.

About the SmartChip Real-Time PCR System

The SmartChip Real-Time PCR System is designed as the first whole genome, high-throughput gene expression real-time PCR platform. This innovative system, combined with next-generation chemistry and optimized assays being developed by WaferGen under the guidance of David Gelfand, Ph.D., Chief Scientific Officer and one of the pioneers of PCR, promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker discovery and validation. The system will provide a number of key ease-of-use features including content-ready chips with gene panels optimized for micro RNA, cancer, and whole genome. WaferGen believes the SmartChip Real-Time PCR System will be the first platform to combine the high-throughput capability and cost efficiencies of existing microarrays, with the sensitivity and accuracy of real-time PCR.

About WaferGen

WaferGen Biosystems, Inc. is a leader in the development, manufacture and sale of state-of-the-art systems for genetic analysis for the life science and pharmaceutical industries. The company is actively developing its SmartChip(TM) product for the gene expression and genotyping markets. WaferGen currently markets its SmartSlide(TM) family of products to companies and organizations involved in stem cell and cell biology research. SmartSlide represents the first fluidics integrated micro-incubators enabling cell biology and stem cell research.

Forward-Looking Statements

This press release contains certain "forward-looking statements". Such statements include statements relating to the expected benefits and advantages of the SmartChip Nano-dispenser, the expected benefits and advantages of the SmartChip technology to other applications, and other statements relating to future events or to the company's future financial performance and are not historical facts, including statements which may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words.

Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that: (i) the company may be unsuccessful in commercially developing its products or in achieving market acceptance of new and relatively unproven technologies; (ii) the company will need to raise additional capital to meet its business requirements in the future and the company may not be able to do so on reasonable terms or at all; (iii) the company's proprietary intellectual property rights may not adequately protect its products and technologies; and (iv) the company expects intense competition in its target markets, including from companies that have much greater resources than the company, and there can be no assurance that the company will be able to compete effectively. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, including the company's Annual Report on Form 10-K for the year ended December 31, 2008 and the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. Investors and security holders are urged to read this document free of charge on the SEC's web site at www.sec.gov. The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

    Contacts:
    WaferGen
    Mona Chadha
    510-651-4450
    Mona.chadha@wafergen.com

SOURCE WaferGen Biosystems, Inc.


'/>"/>
SOURCE WaferGen Biosystems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. WaferGen to Present at the Cambridge Health Institutes Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
5. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
6. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
7. WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference
8. WaferGen Announces Signing of Two Private Placements
9. WaferGen to Present at the Ninth Annual Beyond Genome Conference
10. WaferGen Announces Second Quarter 2008 Financial Results
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... (PRWEB) , ... December 02, 2016 , ... ... innovative U.S.-owned and -operated small businesses in federally funded research and development is ... international society for optics and photonics . , As part of the National ...
(Date:12/4/2016)... 3, 2016  In five studies being presented today ... Meeting and Exposition in San Diego ... improve the delivery of life-saving treatments to patients with ... designed to carry therapies directly to the sites in ... provide a substantial advantage over traditional, systemic methods. The ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation ... and lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland ... AxioMed disc in Bern, Lucerne, and Zurich to discuss the benefits of a ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
Breaking Biology Technology:
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/14/2016)... Fla., Nov. 14, 2016  xG Technology, Inc. ("xG" ... providing critical wireless communications for use in challenging operating ... September 30, 2016. Management will hold a conference call ... 5:00 p.m. Eastern Time (details below). Key ... a $16 million binding agreement to acquire Vislink Communication ...
(Date:6/22/2016)... -- On Monday, the Department of Homeland Security (DHS) ... for the Biometric Exit Program. The Request for Information ... explains that CBP intends to add biometrics to confirm ... States , in order to deter visa overstays, ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):